OVID logo

Ovid Therapeutics Inc. Common Stock

OVID

OVID: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

more

Show OVID Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of OVID by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by OVID's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Sep. 19, 2023
  • Patent Title: Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder Jul. 04, 2023
  • Patent Title: Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders May. 30, 2023
  • Patent Title: Methods and compositions for treatment of epileptic disorders Jul. 26, 2022
  • Patent Title: Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Jun. 21, 2022
  • Patent Title: Use of gaboxadol in the treatment of diabetes and related conditions Apr. 05, 2022
  • Patent Title: Methods for treating aggression associated with alzheimer's disease Mar. 22, 2022
  • Patent Title: Use of mir-92a or mir-145 in the treatment of angelman syndrome Sep. 28, 2021
  • Patent Title: Methods of treating developmental disorders with gaboxadol Aug. 24, 2021
  • Patent Title: Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering Aug. 17, 2021
  • Patent Title: Methods of treating developmental disorders and/or seizure disorders with etifoxine Feb. 23, 2021
  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Dec. 22, 2020
  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Nov. 17, 2020
  • Patent Title: Use of gaboxadol in the treatment of diabetes and related conditions Oct. 27, 2020
  • Patent Title: Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Oct. 27, 2020
  • Patent Title: Methods and compositions for treatment of epileptic disorders Oct. 13, 2020
  • Patent Title: Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering Sep. 08, 2020
  • Patent Title: Methods of treating developmental encephalopathies Sep. 08, 2020
  • Patent Title: Methods of treating developmental syndromes with pde10a inhibitors Aug. 11, 2020
  • Patent Title: Use of mir-92a or mir-145 in the treatment of angelman syndrome Jul. 07, 2020
  • Patent Title: Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction May. 19, 2020
  • Patent Title: Methods of treating behavioral syndromes using pipradrol Dec. 03, 2019
  • Patent Title: Methods of treating developmental disorders with biguanides Oct. 01, 2019
  • Patent Title: Methods of treating developmental disorders and/or seizure disorders with etifoxine Sep. 24, 2019
  • Patent Title: Methods and compositions for treatment of epileptic disorders Jul. 30, 2019
  • Patent Title: Methods of treating seizure disorders Apr. 23, 2019
  • Patent Title: Methods of treating prader-willi syndrome Feb. 05, 2019
  • Patent Title: Use of gaboxadol in the treatment of tinnitus Jan. 29, 2019
  • Patent Title: Methods of treating developmental disorders with biguanides Nov. 13, 2018
  • Patent Title: Methods of sedation during critical care treatment Oct. 30, 2018
  • Patent Title: Use of gaboxadol in the treatment of tinnitus Sep. 11, 2018
  • Patent Title: Methods of treating developmental disorders using pipradrol Mar. 13, 2018
  • Patent Title: Methods of treating behavioral syndromes using pipradrol Nov. 28, 2017
  • Patent Title: Methods of increasing tonic inhibition and treating secondary insomnia Oct. 31, 2017
  • Patent Title: Methods of treatment rett syndrome Aug. 29, 2017
  • Patent Title: Methods of sedation during critical care treatment Aug. 01, 2017
  • Patent Title: Methods of treating dravet syndrome Jun. 20, 2017
  • Patent Title: Methods of treating prader-willi syndrome Apr. 04, 2017
  • Patent Title: Methods of increasing tonic inhibition and treating fragile x syndrome and angelman syndrome Sep. 20, 2016
  • Patent Title: Methods of sedation during critical care treatment Jul. 26, 2016
  • Patent Title: Methods of treating developmental disorders using pipradrol May. 31, 2016
  • Patent Title: Methods of increasing tonic inhibition and treating secondary insomnia May. 17, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of OVID in WallStreetBets Daily Discussion

OVID News

Recent insights relating to OVID

CNBC Recommendations

Recent picks made for OVID stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OVID

Corporate Flights

Flights by private jets registered to OVID